New ETF to focus on companies fighting biological threats

New ETF to focus on companies fighting biological threats
The Pacer fund could invest in stocks of businesses that identify or combat diseases or companies that enable social distancing
APR 23, 2020
By  Bloomberg

As the coronavirus pandemic rattles the globe, companies that focus on protection or recovery from biological threats could become part of an exchange-traded fund.

Pacer ETFs is planning to launch a fund that tracks an index of companies offering products, technologies and services that are currently in high demand. Those stocks range from businesses that could identify or combat diseases to those enabling social distancing and working from home, according to a filing to the Securities and Exchange Commission.

With millions of people around the world stuck in their home offices to help contain the coronavirus outbreak, companies that specialize in remote-working products are becoming a hot spot. And while biotechnology shares haven’t been immune to the huge volatility, they’ve been withstanding it better than the broader market. Developing new drugs isn’t easy, and making bets in biotech comes with the risk of failure. Yet the potential payoff for investors can also be enormous when a new medicine succeeds.

Nasdaq biotechs have outperformed S&P 500 amid volatile market

“There is likely to be demand for a thematic diversified strategy seeking to combat biotechnology threats as COVID-19 has reshaped global economies,“ said Todd Rosenbluth, head of ETF and mutual fund research at CFRA. “However, many of these likely constituents will be in early stages of growth and profitability, while perhaps also trading at a premium due to investor optimism.”

Pacer plans to track the performance of the BioShares BioThreat Index. It seeks to include companies with at least $1 billion in market capitalization and a minimum average daily value traded of at least $2 million for the last six months.

Latest News

RIA moves: True North adds $353M California RIA as SageView grows North Carolina presence
RIA moves: True North adds $353M California RIA as SageView grows North Carolina presence

Plus, a $400 million Commonwealth team departs to launch an independent family-run RIA in the East Bay area.

Blue Owl Capital, Voya strike private market partnership for retirement plans
Blue Owl Capital, Voya strike private market partnership for retirement plans

The collaboration will focus initially on strategies within collective investment trusts in DC plans, with plans to expand to other retirement-focused private investment solutions.

Top Commonwealth advisor to recruiters: Stop with the cold calls already!
Top Commonwealth advisor to recruiters: Stop with the cold calls already!

“I respectfully request that all recruiters for other BDs discontinue their efforts to contact me," writes Thomas Bartholomew.

Why AI notetakers alone can't fix 'broken' advisor meetings
Why AI notetakers alone can't fix 'broken' advisor meetings

Wealth tech veteran Aaron Klein speaks out against the "misery" of client meetings, why advisors' communication skills don't always help, and AI's potential to make bad meetings "100 times better."

Morgan Stanley, Goldman, Wells Fargo to settle Archegos trades lawsuit
Morgan Stanley, Goldman, Wells Fargo to settle Archegos trades lawsuit

The proposed $120 million settlement would close the book on a legal challenge alleging the Wall Street banks failed to disclose crucial conflicts of interest to investors.

SPONSORED How advisors can build for high-net-worth complexity

Orion's Tom Wilson on delivering coordinated, high-touch service in a world where returns alone no longer set you apart.

SPONSORED RILAs bring stability, growth during volatile markets

Barely a decade old, registered index-linked annuities have quickly surged in popularity, thanks to their unique blend of protection and growth potential—an appealing option for investors looking to chart a steadier course through today's choppy market waters, says Myles Lambert, Brighthouse Financial.